Short answer
Tango Therapeutics, Inc. (TNGX) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results covered quarter ended June 30, 2026.
Tango Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026
- Press release issued August 11, 2026 and furnished as Exhibit 99.1
- Investors should review Exhibit 99.1 for financial results and operating metrics
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 revenue $0; net loss $55.3M, or $0.37 per share, versus $38.9M and $0.35 previously
- Cash, equivalents and marketable securities $1.0B, supporting planned Phase 3 advancement and commercialization preparation
- Vopimetostat plus daraxonrasib delivered 92% objective response rate and 90% six-month progression-free survival
- Phase 3 front-line pancreatic cancer trial design targeted for 2H 2026, pending regulatory and collaborator discussions
- R&D expense $37.2M and G&A expense $22.6M, reflecting increased clinical and launch-readiness investment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tango Therapeutics, Inc. 8-K filings
Get the next TNGX 8-K as it lands
Follow TNGX for push alerts, or ask the research agent what this filing means.